We help people get the compensation they deserve.Dupixent® Lawsuit
Patients who took Dupixent® (dupilumab) to treat conditions like eczema may have an increased risk of a cancer called cutaneous T-cell lymphoma. Dupixent lawsuits allege that the drug’s manufacturers failed to properly warn about the potential danger. See if you may be eligible for a Dupixent lawsuit payout.
Why Take Legal Action?
By filing a dangerous drug lawsuit, you can pursue financial compensation and justice from the companies that caused you or a loved one harm.
Results Secured
- $1.75 million for a woman who suffered a pulmonary embolism from the birth control medication Yaz®
- $1.39 million for a woman in Florida who experienced severe side effects from the arthritis drug Vioxx®
- Over $600,000 for injuries related to Abilify® in New York
Understanding Dupixent Lawsuits for T-Cell Lymphoma
Dupixent is a prescription drug used to treat conditions like eczema (atopic dermatitis) and asthma. While many patients have found relief through this injectable medication, serious safety concerns have emerged.
Dupixent lawsuits allege that the medication may increase the risk of developing cutaneous T-cell lymphoma (CTCL), a rare and dangerous form of non-Hodgkin’s lymphoma that affects the skin.
Dupixent Lawsuits 2025
- Increased risk: Patients treated with Dupixent may be at a higher risk of developing cutaneous T-cell lymphoma.
- Failure to warn: Plaintiffs allege that Dupixent’s manufacturers, Sanofi and Regeneron Pharmaceuticals Inc., did not warn about lymphoma risks on the drug’s label.
- Delayed diagnosis: Because CTCL symptoms can mimic eczema, patients may have mistaken cancer warning signs for their existing condition, leading to delayed diagnoses and continued Dupixent use.
- Worsening of cancer: Some lawsuits claim that Dupixent may accelerate or worsen undiagnosed lymphoma.
- Compensation: Patients and families are seeking financial support for medical bills, lost wages, emotional distress, and more.
Eczema patients treated with Dupixent faced a 4.59 times greater risk of developing cutaneous T-cell lymphoma compared to those who did not use the drug, according to Dermatologic Therapy.
Now, patients harmed by Dupixent are fighting back, alleging that they were not given the information they needed to make safe and informed choices about their health.
LawFirm.com works with dangerous drug lawyers who can help victims seek justice and compensation from a Dupixent lawsuit. They’ve secured over $1.6 billion for those harmed by dangerous pharmaceutical drugs and medical devices.
Dupixent and Lymphoma Risk
Dupixent was first approved by the U.S. Food and Drug Administration (FDA) to treat eczema in 2017. Since then, however, multiple cases of cutaneous T-cell lymphoma have been reported in patients after starting the medication.
Dupixent works by altering certain immune system pathways. While this helps manage eczema and asthma symptoms, researchers believe it may also contribute to the development of CTCL or speed up the progression of an undiagnosed lymphoma.
Types of CTCL that may be connected to Dupixent include:
- Mycosis fungoides: The most common type of CTCL, which usually develops slowly, beginning with scaly rashes or raised patches on the skin
- Sezary syndrome: A rare but aggressive form of CTCL that affects both the skin and the blood, often causing widespread redness and more serious complications
Dupixent dangerous drug lawsuits argue that because lymphoma risks were not included on the drug’s warning label, patients may have mistaken early CTCL symptoms for eczema flare-ups, continuing Dupixent treatment and allowing the cancer to worsen.
While CTCL is most often diagnosed in older adults, new research suggests that Dupixent patients are being diagnosed at younger ages, and many cases are identified within 1 year of starting treatment.
“Overall, we find that the use of dupilumab for treating [atopic dermatitis] is associated with an increased relative risk of developing CTCL. This risk is highest in the first year of therapy and in adult patients.”
– Dermatologic Therapy study
Who Can File a Dupixent Lawsuit?
Dupixent lawsuits are filed by patients who developed serious health complications linked to the drug, particularly certain types of cancer.
You may be eligible to file a Dupixent lawsuit if:
- You used Dupixent (dupilumab) to treat eczema, asthma, or another condition
- You were later diagnosed with cancer
If a loved one has passed away, you may be able to file a Dupixent wrongful death lawsuit on their behalf and seek compensation for their medical expenses, pain and suffering, and more.
Each state has a statute of limitations, which sets a strict deadline for filing a Dupixent lawsuit. Missing this window could mean losing your right to pursue compensation.
Call (888) 726-9160 right now or start a chat with a case manager to see if you may be eligible for compensation from a Dupixent lawsuit.
How to File a Dupixent Lawsuit
Filing a lawsuit doesn’t have to be overwhelming. With the right legal team by your side, you can seek compensation and accountability while focusing on what matters most — your health and your family.
An experienced Dupixent lawyer can handle the legal process for you, from gathering medical evidence to negotiating a settlement, so you don’t have to face this battle alone.
A Dupixent lawsuit lawyer can guide you through the process by:
- Confirming your eligibility by offering a free case review
- Collecting evidence like medical records that show your Dupixent use and cancer diagnosis
- Filing your Dupixent product liability lawsuit before the statute of limitations expires in your state
- Pursuing a Dupixent settlement through negotiations with the drug manufacturers
- Representing you in court if a settlement is unable to be reached
Your legal team will work to secure the maximum compensation available for your medical costs, lost wages, and more, while providing guidance and support every step of the way.
Get Help From a Dupixent Lawsuit Lawyer
At LawFirm.com, we know how devastating it is to face unexpected side effects from a drug you trusted. If you or a loved one developed cancer after using Dupixent, we’re here to help you understand your legal options and fight for the justice you deserve.
The product liability lawyers in our network:
- Bring more than 45 years of experience helping victims of injustice
- Can assist victims and families in all 50 states
- Have recovered over $1.6 billion for those harmed by dangerous drugs and medical devices
- Never charge any upfront costs or hourly fees to represent you
Call (888) 726-9160 right now or get a free case review to see if a top Dupixent lawyer may be able to fight for you.
Dupixent Lawsuit FAQs
The controversy around Dupixent stems from claims that the medication may increase the risk of cutaneous T-cell lymphoma (CTCL), a rare and dangerous type of non-Hodgkin’s lymphoma that affects the skin.
Dupixent lawsuits allege that the drug’s manufacturers failed to include warnings about this cancer risk on the label. Because CTCL symptoms can look like eczema, Dupixent users may have mistaken early cancer signs for their skin condition, delaying diagnosis and allowing the disease to progress.
Dupixent has been linked in medical studies and case reports to an increased risk of cutaneous T-cell lymphoma, an uncommon cancer where white blood cells called T-cells turn malignant and attack the skin.
Eczema patients treated with Dupixent were more than 4.5 times likely to develop CTCL compared to those who did not use the drug, according to Dermatologic Therapy.
If you or a loved one has been harmed, you may be eligible for compensation from a Dupixent lawsuit. Get started with a free case review.
Medical studies have linked Dupixent to cases of cutaneous T-cell lymphoma. Types of CTCL associated with Dupixent include mycosis fungoides and the more aggressive Sezary syndrome.
Dupixent may also worsen or accelerate undiagnosed lymphoma, making it harder to treat, as noted in Cureus.
Yes. Dupixent has several long-term side effects, some of which were disclosed by the manufacturers and included on the drug’s warning label. Dupixent can affect the eyes, joints, and skin.
Dupixent side effects include:
- Eosinophilia: High white blood cell counts that may cause fatigue or breathing issues
- Eye problems: Redness, irritation, dry eyes, or vision changes
- Infections: Cold sores or other viral infections
- Joint or muscle pain: Stiffness or ongoing soreness
- New skin conditions: Psoriasis or worsening rashes
Patients may also have a higher chance of developing cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma. While patients were warned about some of these issues, the risk of lymphoma was not included on Dupixent’s warning label.
Dupixent is widely prescribed for eczema, asthma, and related conditions, and many patients tolerate it without severe issues. However, recent research and lawsuits suggest the drug may increase the risk of a cancer known as cutaneous T-cell lymphoma.
As of September 2025, Dupixent lawsuits for cutaneous T-cell lymphoma are being filed as individual cases, not as a class action. This approach allows each patient to pursue compensation based on their own specific damages rather than sharing a single Dupixent settlement with a large group of claimants.
Call (888) 726-9160 right now or chat with a case manager to get the legal help you deserve.
Fact-Checked and Legally Reviewed by: Rae Theodore
Rae Theodore is a writer and editor with more than 30 years of experience in legal publishing. She earned a bachelor’s degree in English from Pennsylvania State University.
- HCP Live. (2024). “Dupilumab for Eczema Linked to Risk Increase for Cutaneous T-Cell Lymphoma.” Retrieved from: https://www.hcplive.com/view/dupilumab-eczema-linked-risk-increase-for-cutaneous-t-cell-lymphoma.
- Journal of the American Academy of Dermatology. (2025). “Commentary: Response to “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study.” Retrieved from: https://www.jaad.org/article/S0190-9622(24)02901-3/fulltext.
- National Library of Medicine. (2024). “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: A retrospective cohort study.” Journal of the American Academy of Dermatology. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/38588818/.
- National Library of Medicine. (2025). “Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.” Retrieved from: https://pubmed.ncbi.nlm.nih.gov/40537179/.
- National Library of Medicine. (2024). “Dupilumab.” Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK585114/.
- National Library of Medicine. (2024). “Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.” Retrieved from: https://pubmed.ncbi.nlm.nih.gov/39668908/.
- Sokolove Law. (2025). “Dupixent® Lawsuit.” Retrieved from: https://www.sokolovelaw.com/dangerous-drugs/dupixent/.
- U.S. Food and Drug Administration. (2024). “October–December 2024: Potential signals of serious risks/new safety information identified by the FDA Adverse Event Reporting System (FAERS).” Retrieved from: https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/october-december-2024-potential-signals-serious-risksnew-safety-information-identified-fda-adverse.
- U.S. Food and Drug Administration. (2022). “Dupixent: Highlights of Prescribing Information.” Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf.
